Associated tags: Diagnosis, Vaccine, COVID-19, Malaria, Hepatitis B, Research, Patient, Environment, Degenerative disease, Herpes simplex, Nature, Therapy, Monkeypox, Viral, Infection
Infection,
Congress,
Recombinant antibodies,
SARS-CoV-2,
Long,
Viral,
ELISA,
ESCMID,
Cytokine,
Epitope,
Lyme disease,
Research,
ELISpot,
Immunology,
Diagnosis,
Long COVID,
Biomarker,
Immunity,
Flow cytometry,
CD8,
Vaccine The Company is hosting at Booth F43, and management will be available for discussions with research organizations and potential partners.
Key Points:
- The Company is hosting at Booth F43, and management will be available for discussions with research organizations and potential partners.
- "We are very pleased to launch ImmuneSelect, an important portfolio of immune profiling solutions within our ViraxImmune™ T-Cell diagnostic platform," commented Mr. James Foster, Chief Executive Officer of Virax Biolabs.
- "The launch marks a significant milestone for Virax as it brings us a step closer to commercializing ViraxImmune™ as a full In-Vitro-Diagnostic product."
- ImmuneSelect is the Company's new portfolio of immune profiling solutions dedicated to investigating adaptive immunity.
Retrieved on:
Thursday, December 21, 2023
Long COVID,
Long,
Urinary tract infection,
Immunology,
University of Manchester,
Immune system,
Research,
Trial of the century,
University,
Viral,
Respiratory disease,
Observational study,
Immunity,
Inflammation,
IVD,
Patient,
Diagnosis,
Vaccine This collaboration aims to apply the ViraxImmune IVD platform to broaden the understanding of T-Cell immune response in COVID patients in the ImRESP (Immunology of Respiratory Conditions) study.
Key Points:
- This collaboration aims to apply the ViraxImmune IVD platform to broaden the understanding of T-Cell immune response in COVID patients in the ImRESP (Immunology of Respiratory Conditions) study.
- Furthermore, within the ImRESP clinical study, the T-cell assay will be assessed in a distinct cohort of patients experiencing Long COVID symptoms.
- This collaboration underscores Virax Biolabs' commitment to advancing diagnostic capabilities and understanding immune responses, particularly in post-viral syndromes and conditions associated with chronic inflammation.
- The collaboration with the University of Manchester represents a significant step toward developing innovative solutions for diagnosing and managing post-viral syndromes.
Retrieved on:
Tuesday, September 12, 2023
The early access program offers select research groups an opportunity to be at the forefront of immune assessment advancements.
Key Points:
- The early access program offers select research groups an opportunity to be at the forefront of immune assessment advancements.
- "We are thrilled to launch this early access program for the RUO of our proprietary ViraxImmune T-cell based test," said Mr. James Foster, Chairman of the Board and Chief Executive Officer of Virax Biolabs.
- The Company will host a webinar for interested research institutions and the investment community on September 20, 2023 at 10 AM ET.
- Participants may register their interest for the event to receive updates and instructions to join the call by visiting https://www.viraxbiolabs.com/viraximmune-early-access-programme .
Retrieved on:
Friday, September 1, 2023
Home Office,
University,
Newcastle upon Tyne,
Justice,
PwC,
University of Strathclyde,
Abbott Laboratories,
Cancer,
Research,
Ministry,
John Lewis Partnership,
King's College London,
Patient,
OTC,
Master,
United Kingdom,
Diagnosis,
Growth,
Ministry of Communications and Information Technology (India),
KPMG,
Pharmacology,
Ministry of Justice,
Management,
Biochemistry LONDON, Sept. 1, 2023 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative diagnostics company focused on the detection of immune responses and diagnosis of viral diseases, announced today the appointment of Dr. Nigel McCracken as the Company's Chief Operating Officer ("COO").
Key Points:
- LONDON, Sept. 1, 2023 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative diagnostics company focused on the detection of immune responses and diagnosis of viral diseases, announced today the appointment of Dr. Nigel McCracken as the Company's Chief Operating Officer ("COO").
- "We are excited to welcome Dr. McCracken to our executive team," commented Mr. James Foster, Chairman of the Board and Chief Executive Officer of Virax.
- Prior to joining Virax, Dr. McCracken was the Chief Scientific Officer at OTC traded BerGenBio AsA where he drove the plan for BerGenBio AsA's companion diagnostics and assay development.
- In addition, Mark Ternouth, Virax's current Chief Technology Officer, will be joining the company's Board of Directors.
Cosmos,
Infection,
CE,
IPO,
Northwestern Bell Telephone Company Regional Headquarters,
IVDR,
Zinc,
Influenza A virus,
Software,
PIPE,
COVID-19,
Immunity,
Research,
Vitamin D,
Dubai Science Park,
CLIA,
Outline,
RUO,
Patient,
Blood,
Vitamin C,
IVD,
Diagnosis,
HC,
Health,
FDA,
Virus,
PCR,
MHRA,
Iron,
Vaccine,
Pharmaceutical industry,
Medical device,
Cryptocurrency,
European LONDON and DUBAI, UAE , June 14, 2023 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative diagnostics company focused on the detection of immune responses and diagnosis of viral diseases, announced that Mr. James Foster, Chairman of the Board & Chief Executive Officer of Virax, has issued a letter to shareholders.
Key Points:
- LONDON and DUBAI, UAE , June 14, 2023 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative diagnostics company focused on the detection of immune responses and diagnosis of viral diseases, announced that Mr. James Foster, Chairman of the Board & Chief Executive Officer of Virax, has issued a letter to shareholders.
- Results will then be delivered directly to an individual through our ViraxImmune™ Mobile Application, providing them an immune profile for a number of viruses.
- We are using COVID-19 as our first target for the in vitro diagnostic T-Cell tests to prove the effectiveness of our technology.
- This will then allow us to adapt to additional pathogens, whether variants of existing pathogens or new ones, as they emerge.
Knowledge,
Heart,
Dubai Design District,
Senior,
D3,
Viral,
Research,
Science,
Dubai Science Park,
TECOM Group,
Patient,
Diagnosis,
Growth,
Ecosystem,
PJSC,
Health,
Director of National Parks,
SME,
Dubai International Academic City,
Vaccine,
Drug LONDON and DUBAI, UAE, May 4, 2023 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative diagnostics company focused on the detection of immune responses to and diagnosis of viral diseases, announced today that it established a regional headquarters at Dubai Science Park, a member of TECOM Group PJSC.
Key Points:
- LONDON and DUBAI, UAE, May 4, 2023 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative diagnostics company focused on the detection of immune responses to and diagnosis of viral diseases, announced today that it established a regional headquarters at Dubai Science Park, a member of TECOM Group PJSC.
- "The new headquarters will strengthen the distribution network we have developed for ViraxClear and enable further development of our innovative technology behind Virax Immune, while tapping into an esteemed science and business community established at Dubai Science Park."
- Dubai Science Park is a global ecosystem that serves the entire value chain of the science, health and pharma sectors.
- Dubai Science Park is part of TECOM Group's portfolio of 10 districts that includes Dubai Internet City, Dubai Media City, Dubai Studio City, Dubai Production City, Dubai Knowledge Park, Dubai International Academic City, Dubai Design District (d3), Dubai Industrial City and Dubai Outsource City.
Retrieved on:
Wednesday, April 19, 2023
Public,
Viral,
Global health,
Infection,
International Health Regulations,
RNA,
Viral hemorrhagic fever,
Marburg virus disease,
Diagnosis,
PCR,
Disease,
World Health Organization,
Vaccine LONDON, April 19, 2023 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotech company focused on the detection of immune responses to and diagnosis of viral diseases, announced today that it has entered into an agreement for the distribution of Marburg Virus PCR testing kits.
Key Points:
- LONDON, April 19, 2023 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotech company focused on the detection of immune responses to and diagnosis of viral diseases, announced today that it has entered into an agreement for the distribution of Marburg Virus PCR testing kits.
- The Marburg Virus Real Time PCR Kit is an in-vitro diagnostic test, based on real-time PCR technology, for the detection of ribonucleic acid (better known as RNA) from the Marburg Virus.
- Our Marburg Virus PCR testing kit is a significant step forward in our mission to improve global health."
- The Marburg Virus Disease is a highly virulent disease which causes hemorrhagic fever and requires assessment under the International Health Regulations by the World Health Organization.
H3,
Poultry,
Infection,
H10,
PCR,
Diagnosis,
Influenza A virus,
H7N9,
AIV,
European,
H5N1,
Human,
Livestock,
Virus,
Viral,
CE,
Vaccine,
H5,
H7 LONDON, March 7, 2023 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative diagnostics company focused on the prevention, detection, and diagnosis of viral diseases, announced today that it has entered into an agreement for the distribution of an Avian Influenza A Virus ("AIV") real-time PCR test kit to markets accepting the CE mark, namely the European Union.
Key Points:
- LONDON, March 7, 2023 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative diagnostics company focused on the prevention, detection, and diagnosis of viral diseases, announced today that it has entered into an agreement for the distribution of an Avian Influenza A Virus ("AIV") real-time PCR test kit to markets accepting the CE mark, namely the European Union.
- The test kit is for the detection and differentiation of ribonucleic acid from AIV and the H5, H7 and H9 subtypes, including the H5N1 strain currently spreading in Europe.
- The test kit is for use in laboratory settings and can help healthcare professionals accurately identify an AIV infection.
- With a real-time PCR test kit poised to accurately and reliably detect AIV, including the deadly H5N1 strain, we expect to facilitate rapid and potentially life-saving interventions especially in vulnerable jurisdictions."
Retrieved on:
Tuesday, February 7, 2023
LONDON, Feb. 7, 2023 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative diagnostics company focused on the prevention, detection, and diagnosis of viral diseases, announced that it has signed a Purchase Order with Cosmos Health (Nasdaq: COSM) ("Cosmos") to launch and market COVID-19 and Influenza A+B Antigen Combo Rapid Detection Kits.
Key Points:
- LONDON, Feb. 7, 2023 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative diagnostics company focused on the prevention, detection, and diagnosis of viral diseases, announced that it has signed a Purchase Order with Cosmos Health (Nasdaq: COSM) ("Cosmos") to launch and market COVID-19 and Influenza A+B Antigen Combo Rapid Detection Kits.
- Virax's Chairman of the Board of Directors and Chief Executive Officer, Mr. James Foster, commented, "COVID-19, Influenza A and Influenza B are major sources of illness and mortality in humans across the globe.
- "While the threat of Influenza has been overshadowed by COVID-19, the healthcare burden of Influenza should not be overlooked.
- The COVID-19 & Influenza A+B antigen combo rapid test is a single-use test kit intended for qualitative detection of nucleocapsid protein antigen of Influenza A and B viral antigens and COVID-19 antigen from nasal swab specimens.
LONDON, Feb. 6, 2023 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative diagnostics company focused on the prevention, detection, and diagnosis of viral diseases, today announced that Dr. Tomasz George, Chief Scientific Officer of Virax, and Cameron Shaw, Chief Operations Officer at Virax, will be presenting at the BIO CEO & Investor Conference on Tuesday, February 7, 2023.
Key Points:
- LONDON, Feb. 6, 2023 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative diagnostics company focused on the prevention, detection, and diagnosis of viral diseases, today announced that Dr. Tomasz George, Chief Scientific Officer of Virax, and Cameron Shaw, Chief Operations Officer at Virax, will be presenting at the BIO CEO & Investor Conference on Tuesday, February 7, 2023.
- The presentation will highlight the recent Company developments, anticipated milestones and ongoing clinical and business developments.
- Details about the presentation are as follows:
Presenters: Dr. Tomasz George, Chief Scientific Officer of Virax, and Cameron Shaw, Chief Operations Officer at Virax
In its 25th year, BIO CEO is one of the largest investor conferences in the life science industry.
- Those interested in scheduling a meeting may do so through the BIO One-on-One Partnering system: https://www.bio.org/events/bio-ceo-investor-digital-conference/partnering .
